Opus Genetics Consensus Price Target Increased 21.47% to $12.98
The average one-year price target for Opus Genetics (NASDAQCM:IRD) has been revised to $12.98 / share. This is an increase of 21.47% from the prior estimate of $10.68 dated August 25, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $8.08 to a high of $21.00 / share. The average price target represents an increase of 117.36% from the latest reported closing price of $5.97 / share, recorded on September 14, 2026. This target range has widened, with the current target range width at $12.92 compared to the prior width of $8.72, representing a change of +48.17%. The current median target has increased to $11.73 from a prior median of $10.20, reflecting an absolute median change of $1.53.
Looking at the historical trajectory of the average target, the mean was recorded at $12.98 on September 15, 2026, up from $10.68 on August 28, 2026, $10.77 on August 4, 2026, and $10.65 on June 30, 2026. This latest mean of $12.98 represents the observed twelve-month high mean, while the observed twelve-month low mean was $6.94 on November 9, 2025. The target has changed by +21.50% since the 90-day baseline date of June 8, 2026. In terms of stock price performance, the shares closed at $5.97 on September 14, 2026, representing a one-week price change of +27.84% from a baseline close of $4.67 on September 4, 2026, and a one-month price change of +65.37% from a baseline close of $3.61 on August 14, 2026.
Opus Genetics, which operates under the description of Ocuphire Pharma, Inc. in the United States, focuses on developing pharmaceutical solutions for eye disorders, including its lead compound Nyxol Eye Drops for night vision disturbances and presbyopia, alongside treatments for diabetic retinopathy and macular edema. The company reported its latest earnings on August 6, 2026, with an actual EPS of -0.08, compared to an estimated EPS of -0.1583. Its actual revenue was $755,000.00, falling short of the estimated $2,494,285.00, which represents a revenue surprise of -69.73%.
Recent analyst actions include Wedbush maintaining an Outperform rating on September 10, 2026, Oppenheimer maintaining an Outperform rating on September 9, 2026, and both BTIG and HC Wainwright & Co. reiterating Buy ratings on September 9, 2026. The recommendation trend has remained steady between August 1, 2026, and September 1, 2026, with a total of 23 recommendations, consisting of 6 strong buy, 16 buy, and 1 hold recommendations, representing 95.7% positive recommendations.
Under the GICS classification, the company is categorized within the Financials sector, Capital Markets industry, and Asset Management & Custody Banks sub-industry. Within this sub-industry, 14 companies are covered, with 5 experiencing raised targets, 2 lowered, and 7 remaining unchanged, yielding a sub-industry median revision of 0.00% and a median implied change of +13.14%. Among its peers in the ophthalmic space, target revisions have remained flat or slightly negative, as shown in the table below.
| Company name | Target revision | Implied change |
|---|---|---|
| Glaukos | 0.00% | +16.95% |
| Ocular Therapeutix | 0.00% | +154.31% |
| Harrow | -3.92% | +88.61% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.